HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35

Benzinga Newsdesk www.benzinga.com Positive 75.1%

Neg 0% Neu 0% Pos 75.1%

HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $30 to $35.